Loading asset research
Q3 2026 earnings · Oct 15
Pulmatrix Inc. Common Stock
PULMNasdaq · USD · StocksQuote as of · Exchange session not verified$1.41
-3.42%
Today
PULM
Loading 1D prices…
Market cap
$5.1M
Volume
7.3K
52w high
$5.5052w low
$1.16Company profile
Pulmatrix Inc. Common Stock
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Framingham, MA, United States
Employees
2
Fiscal year end
1231
CIK
1574235
Session & valuation
Open$1.44
Previous close$1.46
Day high$1.46
Day low$1.41
30-day avg. volume22.4K
Outstanding shares3.7M
Diluted EPS-$1.41
Latest annual period
P/E (trailing)-1.00
P/E (forward)-0.31
Price / book3.23
Beta1.90
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| LABTLakewood-Amedex Biotherapeutics Inc. Common Stock | $5.3M | $0.00 | — | -$2.76 | +8.29% | Unrated |
| CANFCan-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares | $5M | $405K | -2426.67% | -$5.97 | +9.72% | Buy |
| GLMDGalmed Pharmaceuticals Ltd. Ordinary Shares | $4.9M | $0.00 | — | $2.39 | -4.71% | Hold |
| ERNAErnexa Therapeutics Inc. Common Stock | $4.9M | $0.00 | — | -$2.24 | +3.73% | Buy |
| NCNANuCana plc American Depositary Share | $5.5M | — | — | $0.00 | -1.49% | Unrated |